Benitec Biopharma Inc.
BNTCHealthcareNASDAQBiotechnology · Last scanned Oct 21, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Oct 20
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. The $315.3M market capitalization puts BNTC squarely in small-cap range for its industry. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Market Cap
$315.3M
Beta
0.25
P/E (TTM)
—
P/E (Fwd)
-0.96
EPS (TTM)
$-0.98
EPS (Fwd)
$-9.42
ROE
-33.2%
ROA
-22.7%
Cash
$180.0M
Total Debt
$762,000
Free CF
-$2.7M
52W Change
-43.0%
Annual Financials
Cash vs Debt
Where BNTC stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, BNTC finished 30.74% below its 150-day moving average ($11.71) and 30.80% below its 200-day moving average ($11.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BNTC overbought or oversold?
At the October 19, 2026 close, BNTC's RSI(14) was 25.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $180.0M in cash and $762K in debt, BNTC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$2.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -33.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $75K (2023) to $0 (2026), a 100% decline worth watching.
The relatively low beta of 0.25 suggests BNTC is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Benitec Biopharma Inc.'s trajectory.